HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Kenji Suzuki Junji Yoshida Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Suzuki, K. Articles by Nishiwaki, Y. Search for Related Content PubMed PubMed Citation Articles by Suzuki, K. Articles by Nishiwaki, Y.

J Thorac Cardiovasc Surg 1999;118:145-153
© 1999 Mosby, Inc.

GENERAL THORACIC SURGERY

THE PROGNOSIS OF SURGICALLY RESECTED N2 NON–SMALL CELL LUNG CANCER: THE IMPORTANCE OF CLINICAL N STATUS

From the Division of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan.

Supported in part by a Grant-in-Aid for Cancer Research from the Ministry of Health and Welfare.

Address for reprints: Kenji Suzuki, MD, Division of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277 Japan.

Background: Clinical trials dealing with multimodal strategy for N2 non–small cell lung cancer are now being watched with keen interest, and the feasibility of this strategy is to be confirmed. N2 lung cancer, however, is composed of several subgroups with different prognoses. The prognostic factors still remain controversial.
Methods: Between January 1986 and July 1997, 222 patients with lung cancer underwent surgical intervention at our institute; these patients were eventually given a diagnosis of metastasis to ipsilateral mediastinal lymph nodes. All patients underwent mediastinal lymph node dissection or sampling. Sixteen clinicopathologic factors were investigated by univariable and multivariable analyses to identify significant prognostic factors among resected N2 disease. Clinical N status was evaluated by computed tomographic scan.
Results: The overall 5-year survival was 27%. Multivariable analyses among overall patients revealed 4 significant prognostic factors (P < .05): clinical N2 status, incomplete resection, larger tumor size, and multiple diseased N2 nodes. Based on the result, 32 patients with both clinical N2 status and pathologic multiple N2 nodes showed a 5-year survival of 5%, whereas 76 patients with neither of the factors showed a 5-year survival of 57% (P < .001).
Conclusion: The prognosis of surgically resected N2 disease varies tremendously according to the 4 significant prognostic factors. These factors should be clearly described in reporting clinical trials on N2 lung cancer. Clinical N status evaluated by computed tomographic scan should be 1 criterion to perform a clinical trial for N2 disease among a homogeneous population with respect to prognosis. (J Thorac Cardiovasc Surg 1999;118:145-53)

This article has been cited by other articles:

				P. Misthos, E. Sepsas, J. Kokotsakis, I. Skottis, and A. Lioulias The Significance of One-Station N2 Disease in the Prognosis of Patients With Nonsmall-Cell Lung Cancer Ann. Thorac. Surg., November 1, 2008; 86(5): 1626 - 1630. [Abstract] [Full Text] [PDF]

				Z. Mansour, E. A. Kochetkova, N. Santelmo, X. Ducrocq, E. Quoix, J.-M. Wihlm, and G. Massard Persistent N2 Disease After Induction Therapy Does Not Jeopardize Early and Medium Term Outcomes of Pneumonectomy Ann. Thorac. Surg., July 1, 2008; 86(1): 228 - 233. [Abstract] [Full Text] [PDF]

				Y.-C. Lee, C.-T. Wu, S.-W. Kuo, Y.-T. Tseng, and Y.-L. Chang Significance of Extranodal Extension of Regional Lymph Nodes in Surgically Resected Non-small Cell Lung Cancer Chest, April 1, 2007; 131(4): 993 - 999. [Abstract] [Full Text] [PDF]

				K. Takenaka, S. Ishikawa, K. Yanagihara, R. Miyahara, S. Hasegawa, Y. Otake, Y. Morioka, C. Takahashi, M. Noda, H. Ito, et al. Prognostic Significance of Reversion-Inducing Cysteine-Rich Protein With Kazal Motifs Expression in Resected Pathologic Stage IIIA N2 Non-Small-Cell Lung Cancer Ann. Surg. Oncol., October 1, 2005; 12(10): 817 - 824. [Abstract] [Full Text] [PDF]

				L Dertsiz, G Ozbilim, Y Kayisli, G A Gokhan, A Demircan, and U A Kayisli Differential expression of VASP in normal lung tissue and lung adenocarcinomas Thorax, July 1, 2005; 60(7): 576 - 581. [Abstract] [Full Text] [PDF]

				T. J. Lynch, C. D. Wright, N. C. Choi, S. L. Aquino, and E. J. Mark Case 26-2004 - A 56-Year-Old Woman with Cough and a Lung Nodule N. Engl. J. Med., August 19, 2004; 351(8): 809 - 817. [Full Text] [PDF]

				P. Misthos, E. Sepsas, K. Athanassiadi, S. Kakaris, and I. Skottis Skip metastases: analysis of their clinical significance and prognosis in the IIIA stage of non-small cell lung cancer Eur. J. Cardiothorac. Surg., April 1, 2004; 25(4): 502 - 508. [Abstract] [Full Text] [PDF]

				M. Inoue, N. Sawabata, S.-i. Takeda, M. Ohta, Y. Ohno, and H. Maeda Results of surgical intervention for p-stage IIIA (N2) non-small cell lung cancer: Acceptable prognosis predicted by complete resection in patients with single N2 disease with primary tumor in the upper lobe J. Thorac. Cardiovasc. Surg., April 1, 2004; 127(4): 1100 - 1106. [Abstract] [Full Text] [PDF]

				G. Myrdal, M. Lambe, G. Gustafsson, K. Nilsson, and E. Stahle Survival in primary lung cancer potentially cured by operation: influence of tumor stage and clinical characteristics Ann. Thorac. Surg., February 1, 2003; 75(2): 356 - 363. [Abstract] [Full Text] [PDF]

				K. Nagai, R. Tsuchiya, T. Mori, H. Tada, Y. Ichinose, T. Koike, and H. Kato A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209) J. Thorac. Cardiovasc. Surg., February 1, 2003; 125(2): 254 - 260. [Abstract] [Full Text] [PDF]

				Y. S. Choi, Y. M. Shim, J. Kim, and K. Kim Recurrence-free survival and prognostic factors in resected pN2 non-small cell lung cancer Eur. J. Cardiothorac. Surg., November 1, 2002; 22(5): 695 - 700. [Abstract] [Full Text] [PDF]

				G. C. Harewood, M. J. Wiersema, E. S. Edell, and M. Liebow Cost-Minimization Analysis of Alternative Diagnostic Approaches in a Modeled Patient With Non-Small Cell Lung Cancer and Subcarinal Lymphadenopathy Mayo Clin. Proc., February 1, 2002; 77(2): 155 - 164. [Abstract] [PDF]

				Y. Ichinose, H. Kato, T. Koike, R. Tsuchiya, T. Fujisawa, N. Shimizu, Y. Watanabe, T. Mitsudomi, M. Yoshimura, and M. Tsuboi Completely resected stage IIIA non-small cell lung cancer: The significance of primary tumor location and N2 station J. Thorac. Cardiovasc. Surg., October 1, 2001; 122(4): 803 - 808. [Abstract] [Full Text] [PDF]

				A.J. Poncelet, M. Lonneux, E. Coche, B. Weynand, and Ph. Noirhomme PET-FDG scan enhances but does not replace preoperative surgical staging in non-small cell lung carcinoma Eur. J. Cardiothorac. Surg., September 1, 2001; 20(3): 468 - 475. [Abstract] [Full Text] [PDF]